Author | Year | Tumor stage | Neoadjuvant chemotherapy | TNBC | pCR rate of TNBC | non-TNBC | pCR rate of non-TNBC | OR (95% CI) | ||
---|---|---|---|---|---|---|---|---|---|---|
pCR | no-pCR | pCR | no-pCR | |||||||
Rouzier R [8] | 2005 | I, II, III | 12 weeks of P followed by FAC 4 courses (weekly P (80 mg/m2) × 12 + FAC × 4 or 3 weekly P (225 mg/m2) × 4 + FAC × 4) | 10 | 12 | 45.50% | 11 | 49 | 18.30% | 3.71 (1.28, 10.76) |
Carey LA [1] | 2007 | II, III | A 60 mg/m2 + C 600 mg/m2 every 2 weeks or 3 weeks for 4 cycles, either alone or as the first component of a sequential AC-taxane neoadjuvant regimen | 9 | 25 | 26.50% | 8 | 69 | 10.40% | 3.10 (1.08, 8.93) |
Goldstein NS [12] | 2007 | IIA to IIIC | FAC every 3 weeks × 6 FEC every 3 weeks × 6 AC every 2 weeks (dose dense) × 4 then paclitaxel every 2 weeks (dose dense) × 4 AC every 3 weeks × 4 then P every 1 week × 4 | 12 | 9 | 57.10% | 16 | 31 | 34.00% | 2.58 (0.90, 7.41) |
Keam B [13] | 2007 | II, III | D (75 mg/m2 or 60 mg/m2) and A (60 mg/m2 or 50 mg/m2) by intravenous infusion every 3 weeks for 3 cycles | 8 | 39 | 17.00% | 3 | 95 | 3.10% | 6.50 (1.64, 25.78) |
Liedtke C [9] | 2008 | I, II, III | FAC; FEC; weekly or once every 3 weeks P/D followed by FAC; weekly or once every 3 weeks P/D followed by FEC | 57 | 198 | 22.40% | 98 | 765 | 11.40% | 2.25 (1.56, 3.23) |
Bidard FC [14] | 2008 | I, II, III | FEC (F 500 mg/m2, E 100 mg/m2, C 500 mg/m2) or FAC (F 500 mg/m2, A 60 mg/m2, C 500 mg/m2), every 3 weeks for 4 to 6 cycles | 21 | 99 | 17.50% | 7 | 166 | 4.00% | 5.03 (2.06, 12.26) |
Julka PK [15] | 2008 | IIA to IIIB | 4 cycles (21 days) of Gem 1,200 mg/m2 + A 60 mg/m2, 4 cycles of Gem 1,000 mg/m2 plus Cis 70 mg/m2 | 7 | 7 | 50.00% | 6 | 16 | 27.30% | 2.67 (0.65, 10.88) |
Sánchez-Muñoz A [16] | 2008 | II, III | Schedule A: E 90 mg/m2 + C 600 mg/m2 d1 for 3 cycles followed by a second sequence with P 150 mg/m2 + Gem 2,500 mg/m2 d1 ± trastuzumab 2 mg/kg/week according to HER2 status Schedule B: A 40 mg/m2 d1 + P 150 mg/m2 + Gem (2,000 mg/m2) d2, 2 weekly for 6 cycles | 14 | 10 | 58.30% | 17 | 58 | 22.70% | 4.78 (1.80, 12.66) |
Sirohi B [17] | 2008 | M0 | F 200 mg/m2 daily with E 60 mg/m2 and Cis 60 mg/m2 both repeating 3 weekly for 6 courses | 1 | 5 | 16.70% | 5 | 49 | 9.30% | 1.96 (0.19, 20.26) |
Darb-Esfahani S [18] | 2009 | T2 to 3, N0 to 2, M0 | A 50 mg/m2 + D 75 mg/m2 every 14 days for 4 cycles or 4 cycles A 60 mg/m2 plus C 600 mg/m2 every 21 days followed by D 100 mg/m2 every 21 days for 4 cycles | 8 | 25 | 24.20% | 5 | 78 | 6.00% | 4.99 (1.50, 16.65) |
Sikov WM [19] | 2009 | IIA to IIIB | Cb (AUG = 6) every 4 weeks and P 80 mg/m2 weekly for 16 weeks, and weekly trastuzumab was added for HER2(+) status | 8 | 4 | 66.70% | 16 | 25 | 39.00% | 3.13 (0.81, 12.11) |
Bhargava R [20] | 2010 | I, II, III | Anthracycline-based therapy: AC, FEC; taxane-based therapy: T/P + Cb. In many cases a sequential combination of anthracycline and taxane was given: AC-T. The total number of cycles ranged from 4 to 10 with an average of 6 | 24 | 55 | 30.40% | 24 | 256 | 8.60% | 4.65 (2.46, 8.80) |
Chang HR [21] | 2010 | II, III | D (75 mg/m2) and Cb (AUC = 6) were administered every 3 weeks for 4 cycles. Patients with HER2(+) tumors were randomized to receive either additional weekly trastuzumab preoperatively or TC alone | 6 | 5 | 54.50% | 13 | 47 | 21.70% | 4.34 (1.14, 16.51) |
Chavez-Macgregor M [22] | 2010 | M0 | Taxane administered: P 175 to 250 mg/m2 on d1, 3 weekly for 4 cycles; P 80 mg/m2 weekly for 12 doses; or D 100 mg/m2 on d1, 3 weekly for 4 cycles Anthracycline regimens (3 to 6 cycles): F 500 mg/m2, E 100 mg/m2 and C 500 mg/m2 on d1, d3 weekly; F 500 mg/m2 on d1, d4, E 75 mg/m2 and C 500 mg/m2 on d1, 3 weekly | 95 | 395 | 19.40% | 165 | 1419 | 10.40% | 2.07 (1.57, 2.73) |
Chen XS [23] | 2010 | T3 to 4, any N, M0; any T, N2 to 3, M0 | VE: V 25 mg/m2 d1, d8 + E 60 mg/m2 d1, d3 weekly; PCb: P 80 mg/m2 + Cb AUC = 2 d1, d8, d15, 4 weekly; CEF: C 500 mg/m2, E 75 mg/m2 and F 500 mg/m2 d1, 3 weekly; CTF: C 500 mg/m2, THP 50 mg/m2, and F 500 mg/m2 d1, 3 weekly; CEF➝T: D 75 mg/m2 d1, 3 weekly; ED: E 60 mg/m2 + D 75 mg/m2, 3 weekly | 9 | 44 | 17.00% | 19 | 153 | 11.00% | 2.07 (0.86, 4.96) |
Huober J [24] | 2010 | I, II, III | 6 to 8 cycles of TAC (D 75 mg/m2, A 50 mg/m2, C 500 mg/m2 on d1, every 3 weeks) or 2 cycles of TAC followed by four cycles of V 25 mg/m2 on d1, d8 + capecitabine 1,000 mg/m2 orally twice a day on d1 to d14 every 3 weeks | 198 | 311 | 38.90% | 147 | 820 | 15.20% | 3.55 (2.77, 4.56) |
Kim SI [25] | 2010 | M0 | A (50 mg/m2, d1) + D (75 mg/m2, d1) chemotherapy (AT) every 3 weeks for 3 cycles | 16 | 60 | 21.10% | 10 | 181 | 5.20% | 4.83 (2.08, 11.21) |
Pierga JY [26] | 2010 | II, III | E (75 mg/m2) + C (750 mg/m2) intravenously every 3 weeks for 4 cycles followed by D (100 mg/m2) every 3 weeks for 4 cycles with or without trastuzumab (8 mg/kg at first infusion then 6 mg/kg) every 3 weeks | 23 | 55 | 29.50% | 14 | 57 | 19.70% | 1.70 (0.80, 3.64) |
Straver ME [27] | 2011 | T1 to 3, N0 to 2, M0 | AC (6 cycles of A 60 mg/m2 and C 600 mg/m2 every 3 weeks) or AD (6 cycles of A 50 mg/m2 and D 75 mg/m2, every 3 weeks) | 16 | 41 | 28.10% | 13 | 181 | 6.70% | 5.43 (2.43, 12.17) |
Bernsdorf M [28] | 2011 | T2 to 3, N0 to 3b, M0 | 4 cycles of EC (E 90 mg/m2 and C 600 mg/m2) plus 12 weeks of daily treatment with gefitinib 250 mg or EC plus 12 weeks’ treatment with placebo. Chemotherapy was administered every 3 weeks | 12 | 70 | 14.60% | 1 | 47 | 2.10% | 8.06 (1.01, 64.06) |
Iwata H [29] | 2011 | T1c to 3, N0, M0; T1 to 3, N1, M0 | 4 cycles of D (75 mg/m2) administered intravenously every 21 days followed by 4 cycles of FEC (F 500 mg/m2, E 100 mg/m2 and C 500 mg/m2) administered intravenously on d1 every 21 days before surgery | 14 | 15 | 48.30% | 16 | 84 | 16.00% | 4.90 (1.99, 12.09) |
Loo CE [30] | 2011 | T2 to 4, N1 to 3, M0 | Either ER(+) or (–), received 6 courses of AC, administered in a dose-dense schedule (every 2 weeks). A minority received 6 courses of capecitabine + D or doxorubicin + D | 16 | 41 | 28.10% | 22 | 119 | 15.60% | 2.11 (1.01, 4.40) |
Medioni J [31] | 2011 | II, III | Six 2-weekly courses of Gem 1,000 mg/m2 + D 75 mg/m2 on d1, d15 and V 25 mg/m2 + E 100 mg/m2 on d29, d43. Patients with an objective response on d56 then received another cycle of Gem + D on d57 and V + E on d71 | 9 | 13 | 40.90% | 7 | 43 | 14.00% | 4.25 (1.32, 13.65) |
Nakahara H [32] | 2011 | T1 to 4 | HER2(–) tumors started with CE (E 75 mg/m2 × d1 + C 100 mg × daily for 14 days with 7 days’ rest) for 4 or 6 cycles. HER2(+) tumors initiated with CE (E 90 mg/m2 × d1 or E 50 mg/m2 × d1, d8 and C 100 mg × daily for 14 days with 7 days’ rest) | 5 | 13 | 27.80% | 3 | 65 | 4.40% | 8.33 (1.77, 39.27) |
Wu J [33] | 2011 | II, III | P (175 mg/m2) or D (75 mg/m2) + doxorubicin (60 mg/m2) or E (90 mg/m2) every 21 days for a total of 4 cycles | 14 | 40 | 25.90% | 24 | 171 | 12.30% | 2.49 (1.19, 5.25) |
Le Tourneau C [34] | 2012 | II, III | 4 cycles of intensified FAC (A 70 mg/m2 d1, C 700 mg/m2 d1 + d8, and F 700 mg/m2 d1 to d5) every 3 weeks | 9 | 10 | 47.40% | 3 | 30 | 9.10% | 9.00 (2.03, 39.93) |
Ono M [35] | 2012 | II, III | Anthracycline-based regimen (AC: A 60 mg/m2 + C 600 mg/m2 or CEF: C 600 mg/m2 + E 100 mg/m2 + F 600 mg/m2) Taxane-based regimen (weekly P 80 mg/m2 or triweekly D 75 mg/m2) Anthracycline and taxane sequentially or concurrently (A 50 mg/m2 + D 60 mg/m2, AC or CEF followed by weekly P or triweekly D) | 26 | 66 | 28.30% | 9 | 70 | 11.40% | 3.06 (1.34, 7.02) |